论文部分内容阅读
全世界患类风湿关节炎的病人约占总人口的1%。致病原因未明,目前所用治疗方法也都是差强人意的。金诺芬(auranofin)是唯一含金的口服合成抗关节炎新药,由SmithKline & French创制,商品名“Ridaura”。疗效与金注射剂相等,而安全度则过之,使用范围超过其他“病情改善”(disease-modifying)疗法。金诺芬目前已在包括美国、西德、意大利、西班牙、葡萄牙及澳大利亚等在内的35个以上的国家广泛使用。
The world’s patients suffering from rheumatoid arthritis account for about 1% of the total population. The cause of the disease is unknown, the current treatment methods are also unsatisfactory. Auranofin is the only gold-containing oral synthetic anti-arthritic drug manufactured by SmithKline & French under the trade name “Ridaura.” Efficacy is equal to injectable gold, while safety is exceeded, using more than other “disease-modifying” therapies. Jinnuo Fen has been widely used in more than 35 countries including the United States, West Germany, Italy, Spain, Portugal and Australia.